InvestorsHub Logo

$Pistol Pete$

02/18/18 12:37 AM

#178020 RE: $Pistol Pete$ #178019

$DFFN Breaking News DFFN



“We are pleased to be dosing patients so soon following the opening of the INTACT trial just a few weeks ago,” said David Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals. “We believe that this Phase 3 study will offer new hope for inoperable GBM patients who are administered TSC along with their standard therapies.”

http://investors.diffusionpharma.com/file/Index?KeyFile=391934667

mick

02/19/18 11:27 AM

#178137 RE: $Pistol Pete$ #178019

thank you, $CTRV